8-K - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

POS AM - HCW Biologics Inc. (0001828673) (Filer)

SCHEDULE 13G/A - HCW Biologics Inc. (0001828673) (Subject)

10-Q - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

POS AM - HCW Biologics Inc. (0001828673) (Filer)

8-K - HCW Biologics Inc. (0001828673) (Filer)

EFFECT - HCW Biologics Inc. (0001828673) (Filer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

4 - HCW Biologics Inc. (0001828673) (Issuer)

EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced t

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions. Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, "We are pleased to have partnered with HCW Biolo

MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune, cancer and senescence-associated dysplasia, today announced the pricing of its private placement of an aggregate of 2,846,975 units at a purchase price of $1.405 per unit priced at-the-market under Nasdaq rules to a group of healthcare investors (the "Investors"). Each unit consists of (i) one share of common stock at a purchase price of $1.28 per share (or, in lieu thereof, one pre-funded warrant at a purchase price of $1.2799 per pre-funded warrant with an e

DENVER, May 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) - The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative medicine, cell engineering, and AI-assisted drug development continue reshaping investor sentiment. Unlike traditional pharmaceutical compounds, biologics leverage complex biological systems to target diseases with greater specificity, opening new opportunities in cancer, autoimmune disorders, rare diseases, and regenerative therapies. The investment narrative around biologics has expanded far beyond drug development alone. Today, the sector sits at the intersection of artific

MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.

HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight premature infants which the Company believes aligns with newly reauthorized rare pediatric disease and review voucher programs BPD causes abnormal lung development in premature infants that leads to long-term health problems that persist into adulthood as well as neurodevelopmental delays MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immun

MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company's Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time ("Special Meeting") was adjourned, without any business being conducted, due to lack of the required quorum and the matters were adjourned to the Annual Meeting of Stockholders. The proposals presented to stockholders for their consideration at the Special Meeting will be included in the proposals pr

Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation announced today major development regarding

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

 Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has "free" option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced the receipt of ful

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)